Changing Attitudes on Vaccine and Public Health Investment

The Covid-19 pandemic has pushed investment and research into vaccines and public health, but will such interest continue in the long term? Glenn Rockman, founder and Managing Partner of Adjuvant Capital, a VC firm investing in the infectious disease area, believes it will. 

Rockman did not plan to get into life science investment. With a background in public policy and an interest in economics and finance, he decided to go into banking after leaving university.

“I went to work at a big investment bank, JP Morgan, but I didn’t do traditional banking. My clients were limited to what we call ‘mission-driven organizations’ that have a social purpose on top of their institutional purpose.” 

Many organizations fall within this realm, including universities, art museums, and research institutes. But few are as large or as well known as the Bill & Melinda Gates Foundation, which became one of Rockman’s clients.

“One of their biggest priorities was finding a way to convince traditional life science investors that there was an overlooked profit and social impact opportunity in neglected public health challenges,

The post Changing Attitudes on Vaccine and Public Health Investment appeared first on Labiotech.eu.

Published on Wed, 21 Apr 2021 11:30:46 +0000 and brought to you by nintex ticks